These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32746466)

  • 1. Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration.
    de Jager NCB; Heijdra JM; Kieboom Q; Kruip MJHA; Leebeek FWG; Cnossen MH; Mathôt RAA;
    Thromb Haemost; 2020 Oct; 120(10):1407-1416. PubMed ID: 32746466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of the relationship between desmopressin concentration and Von Willebrand factor in Von Willebrand disease type 1: A pharmacodynamic study.
    Heijdra JM; Cloesmeijer ME; de Jager NCB; Leebeek FWG; Kruip MHJA; Cnossen MH; Mathôt RAA;
    Haemophilia; 2022 Sep; 28(5):814-821. PubMed ID: 35526239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.
    Castaman G; Federici AB; Bernardi M; Moroni B; Bertoncello K; Rodeghiero F
    J Thromb Haemost; 2006 Feb; 4(2):357-60. PubMed ID: 16420565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study.
    Heijdra JM; Al Arashi W; de Jager NCB; Cloesmeijer ME; Bukkems LH; Zwaan CM; Leebeek FWG; Mathôt RAA; Cnossen MH;
    BMJ Open; 2022 Feb; 12(2):e049493. PubMed ID: 35168962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
    Castaman G; Tosetto A; Federici AB; Rodeghiero F
    Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
    Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A
    Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates.
    Fressinaud E; Veyradier A; Sigaud M; Boyer-Neumann C; Le Boterff C; Meyer D
    Br J Haematol; 1999 Sep; 106(3):777-83. PubMed ID: 10468873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process?
    Brown SA; Eldridge A; Collins PW; Bowen DJ
    J Thromb Haemost; 2003 Aug; 1(8):1714-7. PubMed ID: 12911582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
    Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
    Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
    Giannini S; Mezzasoma AM; Leone M; Gresele P
    Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD.
    Atiq F; Schütte LM; Looijen AEM; Boender J; Cnossen MH; Eikenboom J; de Maat MPM; Kruip MJHA; Leebeek FWG
    Blood Adv; 2019 Dec; 3(24):4147-4154. PubMed ID: 31834934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease.
    Guddati AK; Rosovsky RP; Van Cott EM; Kuter DJ
    Int J Lab Hematol; 2019 Jun; 41(3):325-330. PubMed ID: 30735311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of desmopressin on plasma factor VIII/von Willebrand factor activity in dogs with von Willebrand's disease.
    Johnstone IB; Crane S
    Can J Vet Res; 1987 Apr; 51(2):189-93. PubMed ID: 3111674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of desmopressin on von Willebrand factor multimers in Doberman Pinschers with type 1 von Willebrand disease.
    Callan MB; Giger U; Catalfamo JL
    Am J Vet Res; 2005 May; 66(5):861-7. PubMed ID: 15938072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease.
    Atiq F; Heijdra J; Snijders F; Boender J; Kempers E; van Heerde WL; Maas DPMSM; Krouwel S; Schoormans SC; de Meris J; Schols SEM; van Galen KPM; van der Bom JG; Cnossen MH; Meijer K; Fijnvandraat K; Eikenboom J; Leebeek FWG
    Blood Adv; 2022 Sep; 6(18):5317-5326. PubMed ID: 35446929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis in von Willebrand disease.
    Franchini M; Targher G; Lippi G
    Ann Hematol; 2007 Oct; 86(10):699-704. PubMed ID: 17634944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Von Willebrand disease: characteristics and response to desmopressin. Study of 103 cases].
    César JM; Avello AG; Vecino A; Cerveró C; Laraña JG; Fuertes IF; Villarrubia J; López J; de Oteyza JP; Velasco JL; Cantalapiedra A; Herrera P; Herrero S; Navarro JL
    Med Clin (Barc); 1998 Nov; 111(16):601-3. PubMed ID: 9881332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
    Federici AB
    Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.